Tumor Targeting: is a cancer treatment that uses drugs.... Targeted therapy works by targeting the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. These genes and proteins are found in cancer cells or in cells related to cancer growth, like blood vessel cells.
The Warburg effect or aerobic glycolysis is a well-known cancer metabolism phenomenon and serves as an established test for tumor detection with FDG-PET scanning technology. Cancer cells swit...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Surface plasmon resonance (SPR) is a sensitive, label-free technique that detects mass changes due to biomolecular interactions on a surface. This versatile method has been used to evaluate t...
Nanotechnology, the engineering and manufacture of materials at the atomic and molecular scale, is used at BIND Therapeutics to develop novel Accurin™ nanomedicines that utilize cytotoxic age...
The webinar will start at 4am Pacific Time, 7am Eastern Time, 1pm Central European Summer Time, 7pm China Standard Time
Extracellular vesicles (EVs) including exosome and microvesi...
DATE: September 9, 2015TIME: 9:00am PDT, 12:00PM EDTDriver mutations are causally implicated in tumorigenesis and disease progression, and they are defined by molecular abnormalities such as ...
DATE: June 17th, 2015TIME: 8am Pacific time, 11am Eastern timeSpatial heterogeneity of tumors has been identified within and between metastatic lesions and can be visualized wit...
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
Asthma is heritable, influenced by the environment, and is modified by in utero exposures and aging; all of these features are also common to epigenetic regulation. Furthermore, genetic varia...
Germline cancer genetics became a reality with the cloning of the tumor suppressor gene RB1 for hereditary retinoblastoma in 1986 by Friend and Weinberg. The existence of cancer susceptibili...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Mass spectrometry (MS)-based profiling of clinical specimens has been increasingly used in cancer research to characterize changes in protein expression between tumor and healthy tissue or be...
Oncogenic mutations in isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) compromise their normal activity and induce NADPH-dependent (D)2-hydroxyglutarate (2HG) production within the cytosol or m...
Advances in genomic research have led to identification of the majority of the drivers of tumor progression. However, our understanding of the molecular mechanisms propelling tumor growth is...
The era of omics has ushered in the hope for personalized medicine. Proteomic and genomic strategies that allow unbiased identification of genes and proteins and their post-transcriptional a...
Cancer research is being revolutionized by targeted gene panels, whole exome sequencing (WES), whole genome sequencing (WGS), and transcriptome sequencing (RNA-Seq).Many analyses, such as...
Tumor cells often display fundamental changes in metabolism and increase their uptake of nutrients to meet the increased bioenergetic demands of proliferation. Glucose and glutamine are two m...
Obesity is associated with an aggressive subtype of breast cancer called basal-like breast cancer (BBC). Using C3(1)-TAg mice, a genetically engineered mouse model that resembles human BBC, w...
As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing...
The modern era of Precision Medicine requires targeted delivery of molecular inhibitors that control key processes in disease pathways. PARP (Poly ADP Ribose Polymerase) plays a crucial role...
Professor Stockwell will discuss the discovery of ferroptosis, a novel model of regulated but non-apoptotic cell death. He will describe how some tumors are sensitized to ferroptosis and may...
This presentation will focus on NuMediis general approach towards the discovery of new therapeutic uses for existing drugs. While the business models for repurposing marketed drugs versus rep...
Late-stage drug attrition rates in oncology remain higher than in other therapeutic areas. To reduce attrition, it is critical to identify appropriate drug targets and pre-clinical models. Th...
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...
The Warburg effect or aerobic glycolysis is a well-known cancer metabolism phenomenon and serves as an established test for tumor detection with FDG-PET scanning technology. Cancer cells swit...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Surface plasmon resonance (SPR) is a sensitive, label-free technique that detects mass changes due to biomolecular interactions on a surface. This versatile method has been used to evaluate t...
Nanotechnology, the engineering and manufacture of materials at the atomic and molecular scale, is used at BIND Therapeutics to develop novel Accurin™ nanomedicines that utilize cytotoxic age...
The webinar will start at 4am Pacific Time, 7am Eastern Time, 1pm Central European Summer Time, 7pm China Standard Time
Extracellular vesicles (EVs) including exosome and microvesi...
DATE: September 9, 2015TIME: 9:00am PDT, 12:00PM EDTDriver mutations are causally implicated in tumorigenesis and disease progression, and they are defined by molecular abnormalities such as ...
DATE: June 17th, 2015TIME: 8am Pacific time, 11am Eastern timeSpatial heterogeneity of tumors has been identified within and between metastatic lesions and can be visualized wit...
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
Asthma is heritable, influenced by the environment, and is modified by in utero exposures and aging; all of these features are also common to epigenetic regulation. Furthermore, genetic varia...
Germline cancer genetics became a reality with the cloning of the tumor suppressor gene RB1 for hereditary retinoblastoma in 1986 by Friend and Weinberg. The existence of cancer susceptibili...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Mass spectrometry (MS)-based profiling of clinical specimens has been increasingly used in cancer research to characterize changes in protein expression between tumor and healthy tissue or be...
Oncogenic mutations in isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) compromise their normal activity and induce NADPH-dependent (D)2-hydroxyglutarate (2HG) production within the cytosol or m...
Advances in genomic research have led to identification of the majority of the drivers of tumor progression. However, our understanding of the molecular mechanisms propelling tumor growth is...
The era of omics has ushered in the hope for personalized medicine. Proteomic and genomic strategies that allow unbiased identification of genes and proteins and their post-transcriptional a...
Cancer research is being revolutionized by targeted gene panels, whole exome sequencing (WES), whole genome sequencing (WGS), and transcriptome sequencing (RNA-Seq).Many analyses, such as...
Tumor cells often display fundamental changes in metabolism and increase their uptake of nutrients to meet the increased bioenergetic demands of proliferation. Glucose and glutamine are two m...
Obesity is associated with an aggressive subtype of breast cancer called basal-like breast cancer (BBC). Using C3(1)-TAg mice, a genetically engineered mouse model that resembles human BBC, w...
As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing...
The modern era of Precision Medicine requires targeted delivery of molecular inhibitors that control key processes in disease pathways. PARP (Poly ADP Ribose Polymerase) plays a crucial role...
Professor Stockwell will discuss the discovery of ferroptosis, a novel model of regulated but non-apoptotic cell death. He will describe how some tumors are sensitized to ferroptosis and may...
This presentation will focus on NuMediis general approach towards the discovery of new therapeutic uses for existing drugs. While the business models for repurposing marketed drugs versus rep...
Late-stage drug attrition rates in oncology remain higher than in other therapeutic areas. To reduce attrition, it is critical to identify appropriate drug targets and pre-clinical models. Th...
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...
Follow
